Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

The effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis.

Doh FM, Chang TI, Koo HM, Lee MJ, Shin DH, Kim CH, Ko KI, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH.

Cardiovasc Drugs Ther. 2012 Dec;26(6):501-9. doi: 10.1007/s10557-012-6412-2.

PMID:
22956052
3.

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN.

Clin Ther. 2010 Mar;32(3):492-505. doi: 10.1016/j.clinthera.2010.03.018.

PMID:
20399986
4.

Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.

Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, Athyros VG, Karagiannis A, Mikhailidis DP, Kita M.

Int J Clin Pract. 2011 Jun;65(6):679-83. doi: 10.1111/j.1742-1241.2011.02655.x.

PMID:
21564441
5.

Low circulating adiponectin levels are associated with insulin resistance in non-obese peritoneal dialysis patients.

Yoo DE, Lee MJ, Oh HJ, Kim SJ, Shin DH, Yoo TH, Kang SW, Choi KH, Han DS, Han SH.

Endocr J. 2012;59(8):685-95. Epub 2012 May 12.

6.

Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).

ter Avest E, Abbink EJ, Holewijn S, de Graaf J, Tack CJ, Stalenhoef AF.

Curr Med Res Opin. 2005 Sep;21(9):1469-76.

PMID:
16197666
7.

Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function.

Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD.

Am J Kidney Dis. 2004 Jun;43(6):1047-55.

PMID:
15168385
8.

Ketoacid Supplementation Partially Improves Metabolic Parameters in Patients on Peritoneal Dialysis.

Dong J, Li YJ, Xu R, Ikizler TA, Wang HY.

Perit Dial Int. 2015 Dec;35(7):736-42. doi: 10.3747/pdi.2014.00151. Epub 2015 Sep 15.

PMID:
26374833
9.

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.

Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS.

Eur J Pharmacol. 2008 Aug 20;590(1-3):327-32. doi: 10.1016/j.ejphar.2008.06.007. Epub 2008 Jun 7.

PMID:
18585701
11.

Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.

Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, Elisaf M.

Int J Clin Pract. 2011 Nov;65(11):1141-8. doi: 10.1111/j.1742-1241.2011.02779.x.

PMID:
21995692
12.

Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.

Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):805-13. doi: 10.5414/CP201735.

PMID:
22943927
13.

Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.

Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, Elisaf MS.

Metab Syndr Relat Disord. 2013 Jun;11(3):152-6. doi: 10.1089/met.2012.0103. Epub 2012 Nov 21.

PMID:
23170931
14.

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.

Lipids Health Dis. 2013 Feb 4;12:9. doi: 10.1186/1476-511X-12-9.

15.

Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.

Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, Siasos G, Papageorgiou N, Papadimitriou CA, Dimopoulos MA, Stefanadis C.

Atherosclerosis. 2010 May;210(1):194-8. doi: 10.1016/j.atherosclerosis.2009.10.046. Epub 2009 Nov 10.

PMID:
19962701
16.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
17.

Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization.

Naples M, Federico LM, Xu E, Nelken J, Adeli K.

Atherosclerosis. 2008 May;198(1):94-103. Epub 2008 Feb 21.

PMID:
18093597
18.
19.

Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.

Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS.

Int J Clin Pract. 2009 Sep;63(9):1308-13. doi: 10.1111/j.1742-1241.2009.02101.x.

PMID:
19691613
20.

[Rosuvastatin improves insulin sensitivity in overweight rats induced by high fat diet. Role of SIRT1 in adipose tissue].

Valero-Muñoz M, Martín-Fernández B, Ballesteros S, Cachofeiro V, Lahera V, de Las Heras N.

Clin Investig Arterioscler. 2014 Jul-Aug;26(4):161-7. doi: 10.1016/j.arteri.2013.12.005. Epub 2014 Mar 4. Spanish.

PMID:
24612843

Supplemental Content

Support Center